Literature DB >> 18162220

Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors.

Mitchell S Cairo1, Vanderson Rocha, Eliane Gluckman, Gregory Hale, John Wagner.   

Abstract

Allogeneic stem cell transplantation has been demonstrated to be curative in a wide variety of pediatric malignant and nonmalignant diseases, and can be traced back over 50 years ago to the original report of Thomas et al. HLA matched sibling donors have been the gold standard for pediatric recipients requiring allogeneic donors for both nonmalignant and malignant conditions. However, only 25% of potential pediatric recipients possesses an HLA-matched sibling donor, and the frequency is even less in those with genetic nonmalignant conditions because of genetically affected other siblings within the family. Therefore, 75% to 90% of potential pediatric recipients require alternative allogeneic donor cells for treatment of their underlying conditions. Potential alternative allogeneic donor sources include unrelated cord blood donors, unrelated adult donors, and haploidentical family donors. In this article we review the experience of both unrelated cord blood donor and haploidentical family donor transplants in selected pediatric malignant and nonmalignant conditions.

Entities:  

Mesh:

Year:  2008        PMID: 18162220     DOI: 10.1016/j.bbmt.2007.10.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

Review 1.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 2.  Cord Blood Banking for Potential Future Transplantation.

Authors:  William T Shearer; Bertram H Lubin; Mitchell S Cairo; Luigi D Notarangelo
Journal:  Pediatrics       Date:  2017-11       Impact factor: 7.124

3.  Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search.

Authors:  A A Hamidieh; M Ostadali Dehaghi; P Paragomi; S Navaei; A Jalali; G Ghazizadeh Eslami; M Behfar; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

4.  Comparison of clinical outcomes between unrelated single umbilical cord blood and "ex-vivo" T-cell depleted haploidentical transplantation in children with hematological malignancies.

Authors:  Carmen Gómez-Santos; Marta González-Vicent; Blanca Molina; Natalia Deltoro; Blanca Herrero; Julia Ruiz; Antonio Pérez-Martínez; Miguel A Diaz
Journal:  World J Pediatr       Date:  2021-09-30       Impact factor: 9.186

Review 5.  New frontiers in pediatric Allo-SCT.

Authors:  J M Talano; M A Pulsipher; H J Symons; O Militano; E B Shereck; R H Giller; L Hancock; E Morris; M S Cairo
Journal:  Bone Marrow Transplant       Date:  2014-05-12       Impact factor: 5.483

6.  Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56Dim NK cells.

Authors:  Evan Shereck; Nancy S Day; Aradhana Awasthi; Janet Ayello; Yaya Chu; Catherine McGuinn; Carmella van de Ven; Megan S Lim; Mitchell S Cairo
Journal:  Innate Immun       Date:  2019-05-08       Impact factor: 2.680

7.  T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCRαβ+/CD19+ Depletion Platforms.

Authors:  Marta Gonzalez-Vicent; Blanca Molina; Ivan Lopez; Josune Zubicaray; Julia Ruiz; Jose Luis Vicario; Elena Sebastián; June Iriondo; Ana Castillo; Lorea Abad; Manuel Ramirez; Julian Sevilla; Miguel A Diaz
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.